ClinicalTrials.gg
RecruitingNCT07235995PAPOD-ESUpdated Oct 29, 2026

Acetaminophen-Mannitol Injection and Postoperative Delirium

A Phase 4 interventional study of Acetaminophen group and Sufentanil group in Postoperative Delirium, sponsored by Xiangya Hospital of Central South University. Recruiting at 1 site in China. Open to participants aged 60 Years and older. Per ClinicalTrials.gov, last updated 2026-10-29.

Sponsored by Xiangya Hospital of Central South University · Phase 4, Interventional, and Prevention

How we know

From the registry’s dates

  • Started Feb 2026; still recruiting 9 months later.
Updated Oct 29, 2026Now RecruitingSite recruiting status changed+4 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
1,092
Allocation
Randomized
Ages
60 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 185 studies in Emergence Delirium with a site in China — 64 open to participants now, 65 under way, 1 of them phase 3. Emergence Delirium · China.

Planned enrollment
10th of 111
1,092 · median 225
Started
2026
with 24 others
Phase 4
31 of 185
9 open now
Primary completion
2027-01
later than 41 of 64 live
Registered
147th of 185
by date

Among the 185 studies in Emergence Delirium with a site in China, this one is the 10th largest by planned enrollment of the 111 interventional ones that give a count, is one of 25 that started in 2026, is one of 31 in phase 4, reaches primary completion later than 41 of the 64 other live ones, and was the 147th registered.

Emergence Delirium

753 studies on the registry are indexed under Emergence Delirium; 261 are open to participants now.

Browse Emergence Delirium studies →

Open to participants now

64 of the 185 studies in Emergence Delirium with a site in China are open now. Recruiting first, the newest first:

58 more — sign in →

All 64 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 141 Emergence Delirium studies recruiting now, 78 (55%) set no upper age limit and 43 (30%) stop at 75 or younger; 33 take children under 18; 24 take healthy volunteers.

This study: 60 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 185 studies in Emergence Delirium with a site in China, or all of them as a file.
02

Study summary

The aim of this multicenter randomized controlled study is to evaluate the effect of an intravenous acetaminophen-mannitol opioid-sparing analgesic strategy on the cumulative incidence of POD, compared with an intravenous sufentanil-based opioid analgesic strategy.

Read the detailed description

Delirium is a common complication after surgery. It is associated with increased morbidity and mortality, longer intensive care unit (ICU) and hospital stay, prolonged mechanical ventilation, higher risk of institutionalization, and higher healthcare cost. Depending on patient population and screening method, the incidence of delirium in elderly patients admitted to ICU can be as high as 58-76%. The choice of analgesics and the adequacy of pain control are among the modifiable precipitating factors for postoperative delirium (POD). Whether the use of intravenous acetaminophen decreases the occurrence of POD in older noncardiac surgical patients admitted to ICU remains inadequately studied.

Objectives: To evaluate the effect of an intravenous acetaminophen-mannitol opioid-sparing analgesic strategy on the cumulative incidence of POD, compared with an intravenous sufentanil-based opioid analgesic strategy, in older noncardiac surgical patients admitted to ICU.

Study design: A randomized controlled trial. Setting: 34 ICUs from different regions across China. Patients: 1092 older patients (≥ 60 years), having noncardiac surgery and admitted to ICU after surgery, are eligible.

Intervention: Patients are randomly assigned to intravenous acetaminophen or sufentanil groups. Intravenous acetaminophen is the analgesic of choice for patients in the acetaminophen group. Intravenous sufentanil is the analgesic of choice for patients in the sufentanil group (control).

Outcomes: The primary endpoint is the incidence of delirium within the first 5 days after surgery. Delirium is assessed using the confusion assessment method for the intensive care unit (CAM-ICU).The secondary outcomes include the duration of delirium occurring within postoperative days 1-5 ;analgesic effect within postoperative days 1-5; cumulative opioid exposure during the 48-hour intervention will be reported as drug-specific cumulative doses, including scheduled sufentanil and all rescue opioids; sleep quality within postoperative days 1-5; length of postoperative ICU stay and hospital stay; incidence of non delirium complications within 30 days after surgery; in hospital and 30 day postoperative all cause mortality, and quality of life and cognitive function in 30 day postoperative survivors. Exploratory outcomes include delirium related biomarkers and neurological function tests measured on postoperative day 1.Safety outcomes include the Hepatic adverse events ,adverse event and Serious adverse event .

Predicted duration of the study: 24 months.

03

Conditions studied

  • Postoperative Delirium

Browse trials for

Keywords

  • Postoperative delirium
  • Intravenous acetaminophen
  • Elderly
  • Noncardiac surgical patients
04

Who can participate

The criteria were revised on the registry on Oct 29, 2026. See what changed

Ages eligible
60 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥ 60 years;
  • Admitted to ICU after a noncardiac surgical procedure
  • Signed form

Exclusion criteria

Exclusion Criteria:

Patients who meet any of the following criteria will be excluded.

  • Preoperative medical history: schizophrenia, epilepsy, Parkinson's disease, end stage renal disease, or end stage liver disease.
  • Inability to communicate preoperatively due to coma, severe dementia, or language disorder.
  • Patients with traumatic brain injury or undergoing neurosurgical procedures.
  • Positive screening result for drugs of abuse (amphetamines, barbiturates, benzodiazepines, cannabinoids, cocaine, methamphetamine, methadone, or methylenedioxymethamphetamine).
  • Participation in another clinical study within 30 days prior to surgery, or planned concurrent participation in another clinical study.
  • Positive preoperative CAM-ICU assessment indicating delirium.
  • Occurrence of intraoperative or postoperative complications before randomization, and the investigator deems the subject unsuitable for study participation.
  • Hepatic dysfunction at screening, defined as or AST >3× the local laboratory (ULN).
  • Intolerance or to acetaminophen or the protocol analgesics.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 4
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
1,092 participants (estimated)

Study arms

  • Experimental
    Acetaminophen group

    Intravenous acetaminophen is the analgesic of choice for patients in the acetaminophen group

    Drug: Acetaminophen group

  • Active comparator
    Sufentanil group

    Intravenous sufentanil is the analgesic of choice for patients in the sufentanil group

    Drug: Sufentanil group

Interventions

  • DrugAcetaminophenStudies of AcetaminophenAcetaminophen pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    The pain in this group is controlled using acetaminophen-mannitol (Paracetamol and Maninitol Injection, Yichang Renfu Medicine Co., Ltd., China), 500 mg, intravenous bolus, every 6 hours for the first 48 hours after randomization. The severity of pain is assessed using NRS/CPOT every 15 minutes during the first hour after randomization with study drug infusion and then once every 12 hours needed.The NRS will be used for awake patients, and the CPOT will be used for mechanically ventilated patients.

  • DrugSufentanilStudies of SufentanilSufentanil pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    The pain in this group is controlled using sufentanil (Yichang Renfu Medicine Co., Ltd., China) intravenous infusion with a rate of 0.05 μg/kg/h. The severity of pain is assessed using NRS/CPOT every 15 minutes during the first hour after randomization with study drug infusion and then once every 12 hours needed.The NRS will be used for awake patients, and the CPOT will be used for mechanically ventilated patients.

06

What researchers measure

Primary outcomes

  1. Incidence of delirium

    Delirium assessed using CAM-ICU every 12 hours (8am, 8 pm) during postoperative days 1-5 and RASS transform at any time

    Time frame: postoperative 1- 5 days

Secondary outcomes

  1. Duration of delirium

    Duration of delirium, defined as the number of postoperative days/hours during which delirium is present.Delirium assessed using CAM-ICU every 12 hours (8am, 8 pm) during postoperative days 1-5 and RASS transform at any time.

    Time frame: postoperative 1- 5 days

  2. Severity of pain

    Severity of pain assessed using numeric rating scale (NRS)/the Critical-Care Pain Observation Tool (CPOT) , 8am and 8pm, twice a day, for 5 day.The NRS will be used for awake patients, and the CPOT will be used for mechanically ventilated patients.The NRS scale consists of 11 points from 0 to 10, where 0 indicates "no pain" and 10 indicates "severe pain". Patients select the corresponding number based on their pain level. \<4 points indicate mild pain (no impact on sleep), 4-6 points indicate moderate pain, and ≥7 points indicate severe pain (pain prevents sleep or causes waking).The CPOT (Critical-Care Pain Observation Tool): Total score range 0-8, where 0 indicates no pain and 8 indicates the worst pain.

    Time frame: postoperative days 1-5

  3. opioid exposure

    Cumulative opioid exposure during the 48-hour intervention will be reported as drug-specific cumulative doses, including scheduled sufentanil and all rescue opioids.

    Time frame: 48-hour after drug infusion

  4. Sleep quality

    Subjective quality of sleep assessed using NRS (an 11-point scale where 0 = the best sleep and 10 = the worst sleep) once daily (8:00-10:00 am) during postoperative days 1-5

    Time frame: postoperative days 1-5

  5. All-cause mortality

    30-days outcome (survival or death) after surgery; Patients will be assessed via phone call if they are discharged before day 30 after surgery

    Time frame: 30-day after surgery

  6. Length of ICU stay

    Postoperative length of ICU stay, defined as the number of days (or hours) from ICU admission to ICU discharge.

    Time frame: From postoperative ICU admission until ICU discharge, assessed for up to 12 months.

  7. Length of hospital stay

    Postoperative length of hospital stay, defined as the number of days/hours from surgery to hospital discharge.

    Time frame: From the day of surgery until hospital discharge, assessed for up to 12 months.

  8. Incidence of non-delirium-related complications

    Complications unrelated to delirium occurring within 30 days postoperatively (e.g., cardiovascular events, cerebrovascular events, renal impairment, GI complications, infections, etc.) are defined as any newly developed complications that may affect patient recovery and require therapeutic intervention (including hospital admission).

    Time frame: 30 days after surgery

  9. Quality of life of 30-day survivors

    Patients will be assessed with World Health Organization Quality of Life Assessment Instrument Short Form (WHOQOL-BREF) via phone call if they are discharged before day 30 after surgery The scale contains 26 items covering four domains: physiological, psychological, social relations, and environmental. It uses a 1-5-point Likert scale for scoring, and the original scores are converted into a standard score of 0-100. The higher the score, the better the quality of life.

    Time frame: day 30 after surgery

  10. Cognitive function of 30-day survivors

    Patients will be assessed with TICS-m via phone call if they are discharged before day 30 after surgery

    Time frame: day 30 after surgery

Other outcomes

  1. Biomarker of delirium

    Biomarker of delirium including S100b and NSE on postoperative day 1

    Time frame: Postoperative day 1

  2. Neuro monitoring of delirium

    Monitoring of neurophysiological function, with detecting SctO2 during postoperative day 1

    Time frame: Postoperative day 1

  3. Safety outcomes

    Safety outcomes will include hepatic safety events, adverse events (AEs), study drug-related AEs, and serious adverse events (SAEs). Each category will be reported separately as the number and percentage of participants experiencing event, together with the timing of event onset.

    Time frame: postoperative days 1-5

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2026 (actual). Primary completion is estimated for Jan 2027, 11 months after the start.

Of 50 non-industry phase 4 interventional studies under Emergence Delirium, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 33. This study's planned 11 months is below that.

Counting every sponsor, half of 50 studies reached it within 19 months; a quarter within 11 and three quarters within 33.

Start moved once since we started tracking on Sep 25, 2026: Dec 2025 → Feb 2026, on Oct 29, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Nov 13, 2025
First posted
Nov 19, 2025
StartActual
Feb 2, 2026was Dec 2025
Primary completionEst.
Jan 31, 2027
CompletionEst.
Apr 30, 2027
Last update
Oct 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Oct 29, 2026
Sites
Xiangya hospital is now Recruiting
Oct 29, 2026
Start date
Dec 1, 2025→Feb 2, 2026 (actual)
Oct 29, 2026
Eligibility
1 inclusion criterion removed; 2 exclusion criteria edited, 8 added, 6 removed
What changed in the criteria
Inclusion criteria
  • RemovedModerate to severe acute pain, with a postoperative pain score ≥ 5 based on the 11-point Numerical Pain Rating Scale (NPRS)
Exclusion criteria
  • AddedPatients who meet any of the following criteria will be excluded.
  • EditedPreoperative medical history: schizophrenia, epilepsy, Parkinson's disease, end stage renal disease, or severe myasthenia gravisend stage liver disease.
  • RemovedHistory of psychiatric disease or significant neurocognitive disorder such as dementia or retardation, making POD assessment impossible
  • RemovedLanguage or communication barrier making POD assessment impossible
  • RemovedIntracranial surgery
  • RemovedSevere hepatic dysfunction prohibiting the use of acetaminophen per the standard of care
  • RemovedParticipation in a competing study within 30d
  • AddedInability to communicate preoperatively due to coma, severe dementia, or language disorder.
  • AddedPatients with traumatic brain injury or undergoing neurosurgical procedures.
  • AddedPositive screening result for drugs of abuse (amphetamines, barbiturates, benzodiazepines, cannabinoids, cocaine, methamphetamine, methadone, or methylenedioxymethamphetamine).
  • AddedParticipation in another clinical study within 30 days prior to surgery, or planned concurrent participation in another clinical study.
  • AddedPositive preoperative CAM-ICU assessment indicating delirium.
  • EditedPatients experiencedOccurrence of intraoperative or postoperative complications before randomization, and the investigator determineddeems the subject was unsuitable to continuefor study participation in the study.
  • RemovedIntolerant to paracetamol or opioid drugs
  • AddedHepatic dysfunction at screening, defined as ALT or AST >3× the local laboratory upper limit of normal (ULN).
  • AddedIntolerance or contraindication to acetaminophen or the protocol analgesics.
Oct 29, 2026
Primary outcomes
1 edited
What changed in the outcomes
  • EditedRateIncidence of deliriumTime frame: postoperative 1- 5 days
Oct 29, 2026
Secondary outcomes
1 edited, 3 time frame changed, 3 added, 4 description edited
What changed in the outcomes
  • AddedDuration of deliriumTime frame: postoperative 1- 5 days
  • Addedopioid exposureTime frame: 48-hour after drug infusion
  • AddedSleep qualityTime frame: postoperative days 1-5
  • Time frameLength of ICU stayimmediately after surgery → From postoperative ICU admission until ICU discharge, assessed for up to 12 months.
  • Time frameLength of hospital stayimmediately after surgery → From the day of surgery until hospital discharge, assessed for up to 12 months.
  • DescriptionLength of ICU stay: how it is measured was reworded
  • DescriptionLength of hospital stay: how it is measured was reworded
  • DescriptionSeverity of pain: how it is measured was reworded
  • Changedother outcomeBefore Sleep qualityNow Safety outcomesTime frame: postoperative days 1-5
  • Time frameother outcomeNeuro monitoring of deliriumPostoperative days 1-5 → Postoperative day 1
  • Descriptionother outcomeNeuro monitoring of delirium: how it is measured was reworded
Oct 29, 2026
Title
Paracetamol and Acetaminophen-Mannitol Injection and Postoperative Delirium
Oct 29, 2026
Show all 1 update
  1. Oct 29, 2026
    Not yet recruiting→Recruiting
    Xiangya hospital is now Recruiting
    Start date Dec 1, 2025→Feb 2, 2026 (now actual)
    Eligibility 1 inclusion criterion removed; 2 exclusion criteria edited, 8 added, 6 removed
    What changed in the criteria
    Inclusion criteria
    • RemovedModerate to severe acute pain, with a postoperative pain score ≥ 5 based on the 11-point Numerical Pain Rating Scale (NPRS)
    Exclusion criteria
    • AddedPatients who meet any of the following criteria will be excluded.
    • EditedPreoperative medical history: schizophrenia, epilepsy, Parkinson's disease, end stage renal disease, or severe myasthenia gravisend stage liver disease.
    • RemovedHistory of psychiatric disease or significant neurocognitive disorder such as dementia or retardation, making POD assessment impossible
    • RemovedLanguage or communication barrier making POD assessment impossible
    • RemovedIntracranial surgery
    • RemovedSevere hepatic dysfunction prohibiting the use of acetaminophen per the standard of care
    • RemovedParticipation in a competing study within 30d
    • AddedInability to communicate preoperatively due to coma, severe dementia, or language disorder.
    • AddedPatients with traumatic brain injury or undergoing neurosurgical procedures.
    • AddedPositive screening result for drugs of abuse (amphetamines, barbiturates, benzodiazepines, cannabinoids, cocaine, methamphetamine, methadone, or methylenedioxymethamphetamine).
    • AddedParticipation in another clinical study within 30 days prior to surgery, or planned concurrent participation in another clinical study.
    • AddedPositive preoperative CAM-ICU assessment indicating delirium.
    • EditedPatients experiencedOccurrence of intraoperative or postoperative complications before randomization, and the investigator determineddeems the subject was unsuitable to continuefor study participation in the study.
    • RemovedIntolerant to paracetamol or opioid drugs
    • AddedHepatic dysfunction at screening, defined as ALT or AST >3× the local laboratory upper limit of normal (ULN).
    • AddedIntolerance or contraindication to acetaminophen or the protocol analgesics.
    Primary outcomes 1 edited
    What changed in the outcomes
    • EditedRateIncidence of deliriumTime frame: postoperative 1- 5 days
    Secondary outcomes 1 edited, 3 time frame changed, 3 added, 4 description edited
    What changed in the outcomes
    • AddedDuration of deliriumTime frame: postoperative 1- 5 days
    • Addedopioid exposureTime frame: 48-hour after drug infusion
    • AddedSleep qualityTime frame: postoperative days 1-5
    • Time frameLength of ICU stayimmediately after surgery → From postoperative ICU admission until ICU discharge, assessed for up to 12 months.
    • Time frameLength of hospital stayimmediately after surgery → From the day of surgery until hospital discharge, assessed for up to 12 months.
    • DescriptionLength of ICU stay: how it is measured was reworded
    • DescriptionLength of hospital stay: how it is measured was reworded
    • DescriptionSeverity of pain: how it is measured was reworded
    • Changedother outcomeBefore Sleep qualityNow Safety outcomesTime frame: postoperative days 1-5
    • Time frameother outcomeNeuro monitoring of deliriumPostoperative days 1-5 → Postoperative day 1
    • Descriptionother outcomeNeuro monitoring of delirium: how it is measured was reworded
    Title Paracetamol and Acetaminophen-Mannitol Injection and Postoperative Delirium
    + 6 other changes: verification date, responsible party, description, conditions, design details and arm descriptions

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07235995
Responsible party
Lina Zhang, MD, PhD (Professor, Xiangya Hospital of Central South University) — Principal investigator
First posted
Nov 19, 2025
Start date
Feb 2, 2026
Primary completion
Jan 31, 2027 (estimated)
Completion
Apr 30, 2027 (estimated)
Last update
Oct 29, 2026

Study contacts

Lina Zhang, Dr.
Contact
zln7095@163.com
86+15874875763
Milin Peng, Dr.
Contact
pengmilin@csu.edu.cn
86+15211040348
Yixiong Li
study chair · Central South University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Acetaminophen

Start the discussion